I knew I was kind of a guinea pig, but the only other option was staying at home, and I wasn’t going to make it,” Tim Story ...

J&J will now pick up almost the full tab for the phase 3 trial, and in return Nanobiotix will see the potential milestone payments that could come its way drop $105 million to $2.6 billion. Shares in ...

A cancer charity has said it is "angry and frustrated" that ministers and health officials have not approved the provision of ...

A previously unknown protein in a family of bacteria found in soil and the human gut microbiome has been discovered—which ...

Scientists from the University of Auckland have discovered that a cancer drug called alpelisib may help extend lifespan—at ...

Six months after publicly revealing his “incurable” cancer diagnosis to the nation, Nigel Latta has said he’s responded well ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest that its novel target has a ...

Karnataka: Shilpa Biologicals Pvt Ltd., a fully owned subsidiary of Shilpa Medicare Limited has signed an exclusive ...